D-0675-2026 Class II Ongoing
FDA drug recall D-0675-2026 was initiated by Cipla USA, Inc. on Jun 29, 2026 and is designated Class II. Reason for recall: cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 8, 2026
- Initiation Date
- Jun 29, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-411-02
Reason for recall
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Distribution pattern
USA Nationwide
Code information
Lot #: 5PB0165, 5PB0166, Exp 1/31/2027; 5PB0552, Exp 4/30/2027; 5PB0642, 5PB0643, 5PB0644, Exp 6/30/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0675-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026